For the year to December 2024, Neurocrine Biosciences had an accrual ratio of -0.15. Therefore, its statutory earnings were very significantly less than its free cashflow. To wit, it produced free ...

Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Ingrezza revenue ...

Neurocrine (NBIX) Biosciences announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares ...

Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market cap of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33.

Following today's announcement of a new iPad Air with an M3 chip, Bloomberg's Mark Gurman now says that Apple plans to announce the long-rumored MacBook Air with the M4 chip tomorrow. "Expect the ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company specializing in neurological and endocrine-related disorders, finds itself at a critical juncture as it navigates a shifting ...

Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a company currently valued at $11.4 billion with strong financial health according to InvestingPro analysis ...

Neurocrine Biosciences has a 52 week low of $110.95 and a 52 week high of $157.98. The firm has a market capitalization of $11.36 billion, a price-to-earnings ratio of 34.64 and a beta of 0.33.

Analysts' ratings for Neurocrine Biosciences NBIX over the last quarter vary from bullish to bearish, as provided by 15 analysts. The table below offers a condensed view of their recent ratings ...